...
首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Intravenous vasopressin for the prevention of nontarget gastrointestinal embolization during liver-directed cancer treatment: Experimental study in a porcine model
【24h】

Intravenous vasopressin for the prevention of nontarget gastrointestinal embolization during liver-directed cancer treatment: Experimental study in a porcine model

机译:静脉加压素在肝癌治疗中预防非目标胃肠道栓塞的研究:猪模型的实验研究

获取原文
获取原文并翻译 | 示例

摘要

Purpose: The aim of this study was to evaluate the potential for intravenous vasopressin to reduce the risk of nontarget gastrointestinal embolization during transcatheter liver-directed cancer therapies in a porcine model. Materials and Methods: An angiographic catheter was used to select the celiac or common hepatic artery under fluoroscopic guidance in six anesthetized pigs. After angiography of the hepatic and splanchnic territories was performed, technetium-99m macroaggregated albumin ( 99mTc-MAA) was injected through the catheter. Serial arteriograms were obtained before, every 5 minutes during, and after peripheral intravenous vasopressin infusion at 0.4 U/min for a minimum of 20 minutes. After 10 minutes of infusion, indium-111 ( 111In)-MAA was injected through the arterial catheter. Quantitative comparisons of liver and gastrointestinal activity using dual-isotope single-photon emission computed tomography (SPECT)/CT imaging were performed. Results: Catheter angiography demonstrated reduced blood flow to the splanchnic vasculature while maintaining blood flow through the hepatic arteries during vasopressin infusion. Angiographic findings correlated with the relative distribution of 99mTc-MAA (before the vasopressin infusion) and 111In-MAA (after the vasopressin infusion) on SPECT/CT. The increased ratio of liver to gastrointestinal tract activity during the vasopressin infusion was statistically significant (6.2:11.4, respectively; P =.018). Conclusions: Intravenous vasopressin reduces arterial blood flow to the splanchnic vasculature while preserving hepatic arterial blood flow in a healthy porcine model. Intraprocedural vasopressin administration has the potential to benefit liver-directed cancer therapies by enhancing tumor targeting as well as preventing the unintended delivery of bland embolic, chemoembolic, or radioembolic agents into the gastrointestinal vascular territories.
机译:目的:本研究的目的是评估在猪模型中经导管肝定向癌症治疗期间静脉内加压素降低非靶标胃肠道栓塞风险的潜力。材料与方法:在六只麻醉的猪中,使用血管造影导管在荧光镜引导下选择腹腔或肝总动脉。在对肝和内脏区域进行血管造影后,通过导管注射tech 99m巨集白蛋白(99mTc-MAA)。在以0.4 U / min的速度进行至少20分钟的外周静脉加压素输注之前,期间和之后,每5分钟和之后获得一系列动脉造影图。输注10分钟后,通过动脉导管注射铟111(111In)-MAA。使用双同位素单光子发射计算机断层扫描(SPECT)/ CT成像对肝脏和胃肠道活动进行了定量比较。结果:导管血管造影显示输注加压素期间,流向内脏脉管的血流减少,同时保持了流经肝动脉的血流。血管造影结果与在SPECT / CT上99mTc-MAA(输注加压素之前)和111In-MAA(输注加压素之后)的相对分布相关。加压素输注过程中肝与胃肠道活性比率的增加具有统计学意义(分别为6.2:11.4; P = .018)。结论:在健康的猪模型中,静脉加压素减少了向内脏脉管系统的动脉血流,同时保留了肝动脉血流。术中使用加压素可能通过增强肿瘤靶向性以及防止将无味的栓塞剂,化学栓塞剂或放射性栓塞剂意外输送到胃肠道血管区域而有益于肝癌治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号